XBiotech Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Sushma Shivaswamy (Interim CEO/Chief Scientific Officer) and Angela Hu (Director of Finance) certified the Q2 2026 10-Q for the period ended June 30, 2026 on August 13, 2026. Both officers affirmed the accuracy of financial statements, effectiveness of disclosure controls and internal controls over financial reporting, and compliance with securities laws. No material weaknesses, significant deficiencies, or management fraud were disclosed.
Why this rating
Boilerplate regulatory certifications. No substantive business developments, financial data, or control deficiencies disclosed. Routine periodic filing requirement.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.